close

Enter

Log in using OpenID

Clostridium Difficile Diagnostics and Treatment Market is Expected to Gain Popularity Across the Globe

embed
The global clostridium difficile diagnostics and treatment market was valued at US$ 1,272.2 million in 2016 and is expected to witness a robust CAGR of 8.2% over the forecast period (2017–2025).
Clostridium Difficile Diagnostics and
Treatment Market Review, Outlook,
Future Analysis And Synthesis By 2025
Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea,
nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and
according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile
infection is the most common healthcare-associated infection. Furthermore, frequent use of
antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill
normal flora (good bacteria) and allow for multiplication of C. difficile bacteria. Common
symptoms of clostridium difficile infection include watery diarrhea, dehydration, fever, nausea,
loss of appetite, and weight loss. Life threatening symptoms of the disease includes abdominal
distension, severe abdominal pain, and profuse diarrhea. Clostridium difficile infection
management includes diagnosis of the infection using various tests and medication therapies
using antibiotics such as Vancomycin and Fidaxomicin.
Request For Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1499
Market Dynamics
Factors such as rising prevalence of clostridium difficile infection, availability of precise and
advanced diagnostic techniques such as real time-polymerase chain reaction (RT-PCR), and
presence of generic versions of standard antibiotics such as metronidazole is expected to boost
growth of the clostridium difficile diagnostics and treatment market over the forecast period.
Furthermore, various organizations and manufacturers are working towards increasing awareness
about clostridium difficile infection and its severity. For instance, in March 2018, C Diff
Foundation awarded its “Making a Difference” award to CutisPharma, Inc.—a pharmaceutical
company, for contribution of the company towards increasing awareness and expanding
treatment options.
Rising prevalence of clostridium difficile infection is expected to boost growth of the
market over the forecast period
Incidence of clostridium difficile infection has been witnessing an increase in the recent past,
due to clostridium difficile infection recurrence and antibiotic resistance. According to Centers
for Disease Control and Prevention (CDC), 2015, around half a million people in the U.S. suffer
from clostridium difficile infection in a year. Moreover, according to National Center for
Biotechnology Information (NCBI), an estimated 37,900 patients were suffering from clostridium
difficile infection in Canada in 2012. A review and meta-analysis of studies published in
National Center for Biotechnology Information (NCBI), 2016, conducted in China between 2010
and 2016 showed significant incidence of clostridium difficile infection in China. Furthermore,
according to Canadian Antimicrobial Resistance Surveillance System 2017 Report, clostridium
difficile infection may be a consequence of commonly prescribed antibiotics for unrelated
infections. According to Organization for Economic Co-operation and Development (OECD),
2015, antibiotic resistant bacteria are highly prevalent in G7 countries. This high presence of
antibiotic resistant bacteria may lead to increasing incidence of the infection, which in turn is
expected to aid in growth of the global clostridium difficile diagnostics and treatment market.
The global clostridium difficile diagnostics and treatment market was valued at US$
1,272.2 million in 2016 and is expected to witness a robust CAGR of 8.2% over the
forecast period (2017–2025).
Report includes chapters which deeply display the following deliverable about industry :
• Clostridium Difficile Diagnostics and Treatment Market Research Objective and Assumption
• Clostridium Difficile Diagnostics and Treatment Market Purview - Report Description,
Executive Summary, and Coherent Opportunity Map (COM)
• Clostridium Difficile Diagnostics and Treatment Market Dynamics, Regulations, and Trends
Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New
system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Clostridium Difficile Diagnostics and Treatment Market, By Regions
• Clostridium Difficile Diagnostics and Treatment Market Competition by Manufacturers
including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales
Area and Product Type.
• Clostridium Difficile Diagnostics and Treatment Market Manufacturers Profiles/Analysis
including Company Basic Information, Manufacturing Base and Its Competitors.
• Clostridium Difficile Diagnostics and Treatment Market Manufacturing Cost Analysis including
Key Raw Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Clostridium Difficile Diagnostics and Treatment Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Top Key Players
Some major players operating in the clostridium difficile diagnostics and treatment market include Roche
AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc.,
Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and
AstraZeneca Plc.
Detailed Segmentation:
Global Clostridium Difficile Diagnostics and Treatment Market, By Product Type:
By Drug
• Metronidazole
• Vancomycin
• Fidaxomicin
• Bezlotoxumab
By Diagnostic Test
• Enzyme Immunoassays
• Real-Time Polymerase Chain Reaction (RT-PCR)
• Nucleic Amplification Tests (NAAT)
• Others
Global Clostridium Difficile Diagnostics and Treatment Market, By Distribution Channel:
• Hospitals & Clinics
• Diagnostic Laboratories
• Pharmacies
Browse Full Report @ https://www.coherentmarketinsights.com/marketinsight/clostridium-difficile-diagnostics-and-treatment-market-1499
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Author
Poul Master
Poul Master247   documents Email
1/--pages
Report inappropriate content